These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27493076)

  • 1. Advanced age negatively impacts survival in an experimental brain tumor model.
    Ladomersky E; Zhai L; Gritsina G; Genet M; Lauing KL; Wu M; James CD; Wainwright DA
    Neurosci Lett; 2016 Sep; 630():203-208. PubMed ID: 27493076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
    Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
    Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
    Wainwright DA; Chang AL; Dey M; Balyasnikova IV; Kim CK; Tobias A; Cheng Y; Kim JW; Qiao J; Zhang L; Han Y; Lesniak MS
    Clin Cancer Res; 2014 Oct; 20(20):5290-301. PubMed ID: 24691018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
    Zhai L; Ladomersky E; Lauing KL; Wu M; Genet M; Gritsina G; Győrffy B; Brastianos PK; Binder DC; Sosman JA; Giles FJ; James CD; Horbinski C; Stupp R; Wainwright DA
    Clin Cancer Res; 2017 Nov; 23(21):6650-6660. PubMed ID: 28751450
    [No Abstract]   [Full Text] [Related]  

  • 5. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
    Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
    Front Immunol; 2020; 11():55. PubMed ID: 32117235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
    Wainwright DA; Balyasnikova IV; Chang AL; Ahmed AU; Moon KS; Auffinger B; Tobias AL; Han Y; Lesniak MS
    Clin Cancer Res; 2012 Nov; 18(22):6110-21. PubMed ID: 22932670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.
    Lukas RV; Juhász C; Wainwright DA; James CD; Kennedy E; Stupp R; Lesniak MS
    J Neurooncol; 2019 Jan; 141(1):111-120. PubMed ID: 30415456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
    Ladomersky E; Zhai L; Lauing KL; Bell A; Xu J; Kocherginsky M; Zhang B; Wu JD; Podojil JR; Platanias LC; Mochizuki AY; Prins RM; Kumthekar P; Raizer JJ; Dixit K; Lukas RV; Horbinski C; Wei M; Zhou C; Pawelec G; Campisi J; Grohmann U; Prendergast GC; Munn DH; Wainwright DA
    Clin Cancer Res; 2020 Oct; 26(19):5232-5245. PubMed ID: 32546647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
    Ladomersky E; Zhai L; Lenzen A; Lauing KL; Qian J; Scholtens DM; Gritsina G; Sun X; Liu Y; Yu F; Gong W; Liu Y; Jiang B; Tang T; Patel R; Platanias LC; James CD; Stupp R; Lukas RV; Binder DC; Wainwright DA
    Clin Cancer Res; 2018 Jun; 24(11):2559-2573. PubMed ID: 29500275
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies.
    Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Sosman JA; Zhang B; Wu JD; Miller SD; Meeks JJ; Lukas RV; Wyatt E; Doglio L; Schiltz GE; McCusker RH; Wainwright DA
    Front Immunol; 2020; 11():1185. PubMed ID: 32612606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
    Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
    Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.
    Hosseinalizadeh H; Mahmoodpour M; Samadani AA; Roudkenar MH
    Med Oncol; 2022 Jun; 39(9):130. PubMed ID: 35716323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
    Guastella AR; Michelhaugh SK; Klinger NV; Kupsky WJ; Polin LA; Muzik O; Juhász C; Mittal S
    Mol Imaging; 2016; 15():. PubMed ID: 27151136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma.
    Sordillo PP; Sordillo LA; Helson L
    Anticancer Res; 2017 May; 37(5):2159-2171. PubMed ID: 28476779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
    Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
    Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.